Bain in the news

  • A Year To Remember For US Drug Launches

    December 29, 2017 | Pharmaceuticals | Scrip | Media mention

    "It's almost like there has been a slow retooling of the entire pharma sector and we are starting to see the results of that happening now," said Michael Retterath, a partner with Bain & Company. "What we saw is pharma retooling and moving into new technologies like gene therapy and CAR-Ts."

  • China FDA's Sovaldi nod could usher in more fast track approvals

    September 29, 2017 | Pharmaceuticals | S&P Global | Media mention

    Due to the Chinese government's recent fast tracking of certain new drugs' approval, more and more international foreign pharma companies will likely try to file applications with the China FDA, according to Phil Leung, a partner with Bain & Company in Shanghai.

  • Bain & Co.'s Rafael Natanek on how to make your drug launch a success

    September 27, 2017 | Pharmaceuticals | S&P Global | Media mention

    Following a survey of 100 executives at the top 20 pharmaceutical companies, Rafael Natanek, a partner with Bain & Company, talked to S&P Global Market Intelligence about the critical importance of a successful new drug launch, given that drug companies will derive 25% to 80% of their revenue from

  • Pharma Investment 2017

    February 07, 2017 | Healthcare | The Deal | Media mention

    Kara Murphy, a partner with Bain & Company and co-lead of the healthcare private equity team, recently participated in a live webcast with The Deal on the topic of investment trends in pharma.

  • Exclusive: Express scripts presses for more drug savings with coverage list

    December 23, 2014 | Healthcare | Reuters | Media mention

    Nils Behnke, partner at Bain & Company, is quoted by Reuters on drug pricing trends. Behnke comments, "when you look at the industry as a whole, we will probably see less profitability.

  • Invent it, swap it or buy it

    November 15, 2014 | Mergers & Acquisitions, Pharmaceuticals | The Economist | Media mention

    Bain & Company partner, Nils Behnke is quoted by The Economist on findings from Bain's M&A pharma research. Behnke explains, "over the period covered by its study, the best-performing drug companies got more than 70% of their revenues from products that were not developed in-house.

  • Bayer’s $14.2 billion Merck buy shows pharma strategy split

    May 07, 2014 | Mergers & Acquisitions, Pharmaceuticals | BloombergBusinessweek | Media mention

    Norbert Hueltenschmidt, a partner at Bain & Company and head of the Healthcare practice in Europe, Africa and the Middle East, comments on the global pharmaceutical industry after Bayer's acquisition of Merck & Co.

  • Diagnostics point to personalised drugs

    July 16, 2012 | Financial Times | Media mention

    Munich partner at Bain & Company, Franz-Robert Klingan, is quoted in a Financial Times article on heathcare. Klingan states, "the pharma industry players these days look at their pipelines and ask if they have a test in development. They absolutely do not want to fall into the Iressa trap again.

  • INSIGHT-Pharma asks the money question earlier for new drugs

    December 20, 2011 | Reuters | Media mention

    Nils Behnke, Bain & Company Healthcare Partner, is quoted in a Reuters article on the reasons pharmaceutical drug development is slowing. Former Pfizer research chief, John LaMattina comments, "When you're doing market research, people are basing their responses and judgments on what's known and

  • A tale of two sectors

    May 17, 2011 | Financial Times | Media mention

    At first glance, few sectors appear more immune to austerity than the drugs business. Growing prosperity and advances in medical science are creating ever-rising demand for healthcare from an expanding global population that is living far longer than before.